Navigation Links
Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
Date:5/26/2009

Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, current economic conditions, foreign currency fluctuations, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some of the associated milestone payments will not be received) and Spectranetics' success in selling the ThromCat(TM) and SafeCross(TM) products, as well as the Company's success in distributing its products into the marketplace, the Company's dependence on four major customers (St. Jude Medical, Arthrex, Orthovita and Spectranetics) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, and competition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligat
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ... are of molecular size less than 10 bps, yet ...
(Date:1/15/2014)... , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ... market as insulin delivery systems especially for ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... 2011 The National Council for Prescription Drug ... on Operating Rules for Information Exchange®) today announced a ... electronic data interchange standards and operating rules across the ... began exploring the potential partnership in late 2010 when ...
... June 15, 2011 Cordis Corporation, a ... vascular technology, today announced it will no longer pursue ... order to focus on other cardiovascular therapies where significant ... manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary ...
Cached Medicine Technology:NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 2NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 3Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 2Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 3Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent 4
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... MONDAY, Feb. 23 (HealthDay News) -- Climate change will ... for respiratory problems, a European study finds. , The ... admission data in 12 European cities. They found ... a city,s maximum apparent temperature (Tappmax), there was a ...
... Purse and Gift of Life, patients travel to United States,**Media Note: ... February 24**, , ... Washington, DC --On February 12, ... Center to correct severe heart defects. Without cardiac surgery, the ...
... America, Inc. today announced that KAPIDEX(TM) (dexlansoprazole) delayed release ... KAPIDEX, available in 30 mg and 60 mg ... Drug Administration (FDA) for the treatment of heartburn associated ... of erosive esophagitis (EE) and the maintenance of healed ...
... Monterey Bay Aquarium Research Institute recently solved the half-century-old ... transparent head. Ever since the "barreleye" fish Macropinna ... have known that it,s tubular eyes are very good ... be fixed in place and seemed to provide only ...
... has teamed up with world famous "Hippocrates Health Institute" ... Clients of HHI are now able to take advantage ... toxins, the source of what many doctors and alternative ... most health problems including obesity, skin problems, and even ...
... health information is compiled on medical sites on ... attentive to their medical conditions and seeking out ... and useful resources, Brooks established the Brooks ... Resource Center is a computer-based learning ...
Cached Medicine News:Health News:Global Warming May Bring More Respiratory Woes 2Health News:Ugandan Children Receive Life-Saving Treatment For Heart Defects At Children's National Medical Center 2Health News:Ugandan Children Receive Life-Saving Treatment For Heart Defects At Children's National Medical Center 3Health News:Ugandan Children Receive Life-Saving Treatment For Heart Defects At Children's National Medical Center 4Health News:KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD 2Health News:KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD 3Health News:Researchers solve mystery of deep-sea fish with tubular eyes and transparent head 2Health News:Researchers solve mystery of deep-sea fish with tubular eyes and transparent head 3Health News:LuxSauna Teams With World Famous Detox Health Retreat 'Hippocrates Health Institute' 2Health News:Brooks Establishes Community Resource Center Web Site 2
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
PremierEdge™ Tunnel Knives....
PremierEdge™ Clear Cornea Knives - Parallel Sides....
Medicine Products: